Three major loci have been associated with HbF levels, including -158C/T (XmnI) at HBG2 promoter region, and several polymorphisms at BCL11A intron-2 and HBS1L-MYB (HMIP) intergenic region. Mutations in the KLF1 gene were recently associated with increased HbF levels. This study aims to evaluate whether genetic variability at these loci influence HbF levels in β-thalassemia carriers and in normal individuals of Portuguese origin. Sixty five β-thalassemia carriers, HbF levels ranging from 0.2% to 9.5%, and 60 individuals with normal haematological parameters, HbF levels ranging from 0.2% to 7.4%, were selected for this study. In β-thal carriers linear regression models revealed strong statistical significant association for HBG2 (XmnI) rs7482144 (β=0.45; P=5.85x10 -7 ), and nominal significance for BCL11A rs766432 (β=0.21; P=0.02) and HMIP rs9399137 (β=0.20; P=0.01). In normal individuals, a case (HbF>2%; n=15) vs. control (HbF<1.7%; n=45) model, showed nominal significant associations for BCL11A SNPs rs11886868 (OR=4; P=0.001), rs766432 (OR=3.7; P=0.002) and rs7606173 (OR=0.36; P=0.03). KLF1 rs3817621 was not found associated with HbF levels. Our results suggest that in Portuguese β-thal carriers the HBG2 XmnI polymorphism is strongly associated with HbF levels. In normal individuals, BCL11A polymorphisms, but not HMIP or HBG2 (XmnI) loci, are nominally associated with HbF expression.
INTRODUCTION
Fetal hemoglobin (HbF, α2γ2) levels vary among individuals as a consequence of genetic variation. The identification of modulators responsible for the reactivation of gamma-globin genes has been extensively studied, since high levels of HbF contribute to ameliorate the clinical manifestations and severity of sickle cell anemia (SCA) and β-thalassemia (β-thal) [1, 2] . Thus, the understanding of these modulation factors and how the fetal to adult (γ to β) globin chains switch occurs in the course of human ontogeny could be important to identify targets for the development of new therapies to improve the treatment of these hemoglobinopathies [1, 2] .
Recent genome wide association studies (GWAS), conducted in both healthy nonanemic populations and in patients with sickle cell disease or beta thalassemia of European, African or Asian descent, have identified several single nucleotide polymorphism (SNP) variants along the genome associated with HbF levels (or the highly correlated F-cells number). The three important HbF levels loci determinants identified were: i) SNPs at promoter nucleotide of HBG2 on chromosome 11p15, including the -158 C/T (rs7482144) variant also known as XmnI; ii) SNP variants located at the HBS1L-MYB intergenic region (HMIP) on chromosome 6q23, and iii) SNPs located at the BCL11A gene on chromosome 2p16 [1, 3, 4, 5] . The erythroid transcription factor KLF1 activates BCL11A and assists in coordinating the switch from fetal to adult hemoglobin [6] .
Individuals with loss-of-function KLF1 mutations were known to have persistently elevated HbF [7] [8] [9] .
A modest elevation of HbF (1-5%), called heterocellular hereditary persistence of fetal hemoglobin (HPFH) or Swiss type HPFH, is observed in 10-15% of apparently normal individuals in the absence of any hematological disorder [10] . This condition had been regarded as a multifactorial quantitative trait linked to polymorphic variations in regulatory sequences of the -and β-globin genes, especially the -158 C>T polymorphism [11] [12] [13] , or in introns of -genes, but also with other loci mapping elsewhere in the genome (Xp 22.2-22.3 region, 6q23 and 8q) [14] [15] [16] .
In beta-thalassemia, the synthesis of the β-globin polypeptide is reduced as a result of mutations in this gene, leading to an excess of alpha-globin chains which precipitate in red blood cell precursors, contributing to dyserythropoiesis and premature cells death [17] . Ineffective production of mature red blood cells in homozygotes or compound heterozygotes for β-globin mutations leads to anemia with severely clinical manifestations (β-thalassemia major and β-thalassemia intermedia) [17] . Increased production of -globin chains can modulate the disease severity by reducing the number of free α-chains, which decreases the dyserythropoiesis [18, 19] . Carriers of β-thalassemia (β-thal minor) have a mild asymptomatic anemia with no 4 clinical symptoms. Several genetic association studies have been performed in β-thal carriers across different populations and have identified sequence variants associated with the HbF levels [20] [21] [22] [23] .
Nevertheless, results regarding the genetic association basis for both conditions, β-thal carriers and HPFH, are not entirely clear, and some loci previously identified in patients with severe hemoglobinopathies have not yet been assessed in such individuals. Thus, the aim of this study was to evaluate whether genetic variability in loci BCL11A, HMIP, HBG2 and KLF1 are associated with HbF levels in normal subjects with common forms of HPFH and in β-thal carriers of Portuguese origin.
MATERIAL AND METHODS

Study population
A total of 125 unrelated subjects of Portuguese origin were recruited for this study, including heterozygous for beta thalassemia mutations and HBB wild-type.
Sixty five (35 females and 30 males) were beta thalassemia carriers, aged 2-77 years (mean age 34.3 y; median age 35 y), with HbF levels ranging from 0.2% to 9.5% and HbA2 levels raised between 3.4% and 6.8% (mean 4.78%). These subjects classified as β-thal minor were heterozygous for one of the following mutations in the HBB gene A second population group of 60 subjects (34 females; 26 males), aged 2-75 years (mean age 29.87 y; median age 30 y), with normal hematological parameters, HbF levels ranging from 0.2% to 7.4% and normal HbA2, was selected: a control group of randomly recruited subjects (n=35) with normal HbF levels ranging from 0.2% to 1.6%, and 15 subjects with HbF levels >2%, classified as HPFH. 
Genotyping
Seven SNPs were chosen for this study based on the recent publications in PubMed reporting genetic variants most strongly associated with increased HbF levels: loci BCL11A (rs11886868, rs766432 and rs7606173), HBS1L-MYB (HMIP) (rs9399137 and rs6934903), HBG2 (rs7482144), and KLF1 (rs3817621). SNPs rs11886868, rs7606173, rs9399137 were genotyped by TaqMan assay using pre-designed probes (Applied Biosystems, Foster City, USA). Allelic discrimination was performed according to the manufacturer's instruction on a BioRad RT-PCR system (MiniOpticon, BioRad, CA, USA). SNPs rs766432, rs6934903, rs7482144 and rs3817621 were genotyped by PCR-RFLP using the restriction enzymes AccI, HpyCH4III, XmnI, and AciI, respectively. To assess genotyping reproducibility, 10% of random samples were and regenotyped for all SNPs with 100% concordance.
A commercially available kit (SALSA MLPA kit P102-B2 HBB), using multiplex ligationdependent probe amplification (MLPA), was used to screen for deletions in the beta-globin cluster for individuals with HbF levels >5%.
Statistical analysis
The allelic and genotypic frequencies of all polymorphisms were estimated by direct counting and Hardy-Weinberg equilibrium probability values were achieved using an exact test.
Associations of SNPs with HbF levels, after logarithmic transformation to near normalize the quantitative trait distribution, were performed: i) in the β-thal minor group by linear regression under an additive genetic model; ii) in the normal subjects by a case-control model (subjects with HPFH vs. subjects with normal HbF), using 2% HbF as cutoff-point, estimating P values, odds ratio (OR), and 95% confidence intervals (CI), crude and with age and sex as covariates. All these statistical analyses were done using the set-based tests implemented on PLINK software v.1.07
(http://pngu.mgh.harvard.edu/purcell/plink/) [24] .
Graphical analyses, normality of the data assessed by the Kolmogorov-Smirnov test and comparisons of HbF levels between genotypes by using non-parametric (Mann-Whitney U for β-thal carriers) or parametric (one way ANOVA, followed by post hoc Bonferroni test for normal individuals) tests according to the distribution of data, were performed with the SPSS software, version 20.
A significant p-value was considered below 7.1x10 -3 (0.05/7) by applying a Bonferroni correction for multiple testing, and a p-value below 0.05 was considered significant for individual SNPs.
RESULTS
The demographic characteristics and hematological parameters of the populations under investigation are shown in Table 1 .
Beta thalassemia carriers
Regarding the β-thal minor group, total genotyping rate was 0.942. The minor allele frequencies (MAF) observed for the seven polymorphisms in the total sample were displayed in Table 2 . The genotype distributions were in agreement with the Hardy-Weinberg equilibrium (P>0.05). Deletional mutations in the -genes cluster were excluded in individuals with HbF levels >5%.
Using a dominant model (genotypes homozygous for the ancestral allele versus homozygous and heterozygous for the derived allele), we analysed the distribution of log transformed HbF values according to SNP genotypes by the Mann-Whitney U test (Table S1 ). Significant differences were observed for SNPs BCL11A rs766432 (P=0.034), HMIP rs9399137 (P=0.005) and HBG rs7482144 (P<0.001). ) and nominal significant association with SNPs BCL11A rs766432 (β=0.22; P=0.029) and HMIP rs9399137 (β=0.21; P=0.011), also using age and sex as covariates (P=0.011, P=0.018 and P=6.77x10 -7 , respectively) ( Table 2) .
Normal subjects
In relation to the normal subjects, genotyping rate was 0.998. The MAF were presented in Table 3 for all the studied polymorphisms. Genotype distributions were in agreement with
Hardy-Weinberg equilibrium (P>0.05). No deletional mutations were detected in the -genes cluster among subjects with HbF levels >5%.
We analysed the log transformed HbF mean values according to SNP genotypes by one-way ANOVA and statistical significant differences were observed for the BCL11A SNPs rs11886868 (P<0.001), rs766432 (P=0.008) and rs7606173 (P=0.006) (Table S2 ). Individuals homozygous for the derived allele at rs11886868 (CC) and rs766432 (CC) and for the ancestral allele at rs7606173
(GG) have HbF levels about 3 times higher than those homozygous for the different allele (Bonferroni post-hoc tests: P<0.001, P=0.008 and P=0.004, respectively). The distribution of HbF levels (log-transformed) within each genotype group of the three BCL11A SNPs in box-plots (Figure 2 ), show the homozygous individuals for the ancestral allele at rs11886868 (TT) and rs766432 (AA) and for the derived allele at rs7606173 (CC) with the lowest HbF values.
We subdivided participants in two groups considering the HbF levels: a group (n = 15) with levels of HbF between 2% and 7.4%, classified with HPFH, and a group (n= 45) with HbF levels in the normal range, below 2% (0.1% to 1.6%). The mean of HbF (4.28% vs. 0.67%) differs significantly between the two groups (P<0.001). The case-control study, under an additive model, showed nominal significant associations between BCL11A SNPs rs11886868 (OR=4; 95%
CI, 1.6-9.6; P=0.001), rs766432 (OR=3.7; 95% CI, 1.5-8.9; P=0.002) and rs7606173 (OR=0.36; 95% CI, 0.14-0.93; P=0.03) and HbF levels ( 
DISCUSSION
Individuals with severe forms of hemoglobinopathies due to beta-globin chain disorders, including beta-thalassemia major and intermedia and sickle cell disease, typically demonstrate clinical phenotypes whose severity is inversely proportional to the degree of preservation of HbF expression. Common polymorphisms at just three loci account for a meaningful fraction of the variation in HbF levels. These loci include the beta-globin gene cluster itself, an intergenic interval between the HBS1L and MYB genes (HMIP) and BCL11A.
The rs7482144 C/T polymorphism (XmnI), located at the promoter region of the HBG2 gene, has been associated with an enhancement of HbF levels under erythropoietic stress in homozygous  + -thalassemia [25] or sickle cell anemia [4, 23] , but also with a modest elevation of HbF (1-5%) in normal individuals in several association studies [11] [12] [13] . In a group of Portuguese β-thal carriers we have found a strong association between increased HbF levels and the rs7482144 T allele, which confirms previously described associations of the HBG2 -158T
allele (XmnI Gγ+) with increased levels of HbF in β-thal carriers of Portuguese [23] , Italian [20] and Indian [22] descent. However, our study did not show statistical significant correlations in normal subjects with HPFH regarding the effect of the HBG2 XmnI polymorphism on the synthesis of HbF levels. Although this result is in contrast with other studies in normal individuals from Algerian [12] and Tunisian [13] populations, our findings are in accordance to previous reports for minor or absence of consequences on HbF levels in normal individuals of Italian [20] and Indian [22] origin. These inconsistent results regarding normal subjects may depend on the different statistical models used in the analysis or to the lower cutoff point (~1%) used to distinguish normal versus raised HbF levels in case-control studies [12, 13] . We have used a 2% cutoff as a limit for the normal HbF to overcome eventual discrepancies in the lower quantifications by the HPLC method. Moreover, linear regression models to assess the correlation of polymorphisms in individuals with HbF levels between 0.1 and 1.7 (i.e., below the considered cutoff point of 2%) did not show significant association with HbF for the XmnI polymorphism.
BCL11A expression is important for gamma to beta globin gene switching and the increase in HbF is associated with reduced BCL11A expression [26] . Several studies validated BCL11A as a transcriptional repressor acting in the HBG promoter to form a repressor complex [27, 28] . Xu et al [29] using a sickle cell disease mouse model demonstrate that interference with BCL11A function increases fetal hemoglobin levels and, thereby, reduces the severity of the disease.
These data illustrates the potential of the transcription factor BCL11A as a therapeutic target for the treatment of sickle cell disease and beta-thalassemia. Variation at BCL11A gene is estimated to explain ~15% of the variance in HbF levels and several SNPs have been identified within 20 kb in BCL11A intron-2 as the most highly associated with the HbF, including rs11886868 [18] , rs766432 [5] and rs7606173 [2] . These SNPs lie within an erythroid enhancer and act combinatorial to influence BCL11A regulation [30] . Our studies in the Portuguese normal subjects showed that these three BCL11A SNPs, rs11886868, rs766432 and rs7606173 are nominally associated with HbF values. The haplotype analysis showed haplotype CCG, with the three HbF associated alleles, significantly associated with HbF (P=0.002).This is in concordance with previous data at BCL11A showing that the rs11886868 genotype distribution was markedly different between Sardinian individuals with normal HbF values and those with HPFH [18] . In regarding to β-thal carriers, our data show nominal significant association between BCL11A rs766432 and HbF levels, as previous found in Chinese adult β-thal heterozygotes [21] .
Regarding the HBS1L-MYB intergenic region (HMIP), the most significant associated SNP in betathalassemia and sickle cell anemia among Chinese, European, and African patients, was rs9399137, located at the haplotype block 2 [1] . Overexpression of MYB, a critical regulator of erythroid development, but not HBS1L, in human K562 erythroid cells was shown to decrease HBG expression [31] ; and down-regulation of MYB expression in adult erythroid cell cultures by shRNAs was reported to result in increased HBG expression [32] . More recently, functional studies using human erythroid progenitors (HEPs) showed that several HBS1L-MYB intergenic variants located in regulatory elements may reduce transcription factor bindings, affecting longrange interactions with MYB; this results in decreased MYB expression and consequently elevated HbF levels [33] . Our data in β-thal carriers showed nominal statistically significant associations between HMIP rs9399137 and HbF levels, replicating previous findings in Chinese adult β-thal heterozygotes [21] . However, no significant correlation with HbF levels was found in our study sample of normal individuals for the HMIP variants. This result is different from previous findings regarding the association of rs9399137 with HbF levels in normal subjects of northern European origin [3] .
BCL11A controls the HBB cluster in association with the erythroid KLF1 transcription factor.
The KLF1 transcription factor occupies the BCL11A promoter and it is known that knockdown of KLF1 leads to decreased BCL11A in human erythroid progenitors, derepressing -globin chains synthesis [6, 7] . Several point mutations in the KLF1 gene were found to be associated with HPFH.
These KLF1 mutations are predicted to affect gene function, and include missense mutations, frameshift mutations, deletions, splice site and nonsense mutations [7, 8] . Moreover, a first KLF1
gene promoter mutation (-148G>A) was also associated with increased HbF levels in an adult female subject of Serbian origin [9] . This mutation is located within a Sp1 binding site, resulting in drastically reduced CAT reporter gene expression in K562 cells and in reduced KLF1 gene expression in vivo [9] . In our work, trying to identify additional KLF1 gene promoter variations that could be associated with HbF levels, we investigated a common SNP G/C (rs3817621), located 102 bp upstream the -148G>A variant, which has a minor allele frequency of 25% in the European population (1000 genomes project EUR population, http://www.ensembl.org/). The no significant association between rs3817621 and HbF levels, observed both in β-thal carriers and wild-type individuals, may be explained by the high population frequency of this variant, in contrast to the rare KLF1 -148G>A variation (rs79334031), with a 4% frequency for the minor Aallele in the European population (1000 genomes project EUR population, http://www.ensembl.org/), and located in a functional element of the KLF1 promoter region.
In conclusion, our results suggest that the increase of HbF levels in Portuguese individuals with normal hematological parameters is nominally associated with BCL11A polymorphisms, but not with HMIP or the HBG2 XmnI polymorphisms. On the other hand, the increase of HbF levels in Portuguese β-thal carriers is strongly associated with the HBG2 XmnI polymorphism, but also with BCL11A rs766432 and HMIP rs9399137. These results are consistent with previous findings in European and other populations. Fi Table 1 : Description of demographic and hematological data (mean ± SD) in the two population groups studied: beta-thalassemia carriers and subjects with normal hematological parameters.
Characteristics β-thal minor Normal individuals
Age (mean ± SD) (years old) 33 Hematological parameters on 53 (*) and 39 (**) subjects with β-thal minor, and 29 (*) and 22 (**) normal subjects. 
Abbreviations:
n: number of subjects within each genotype. P*: Bonferroni post-hoc p-values for multiple comparisons, between homozygous genotypes for the ancestral allele and heterozygous and homozygous genotypes with the derived allele. P**: P-value obtained with ANOVA. HbF levels shown are not-transformed. Significant P-values (P<0.05) are in bold.
